NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC

NCT03995875

CompletedN/A

Sponsor: AstraZeneca

Conditions: Carcinoma, Non-Small-Cell Lung

Countries: Japan

This observational study is designed to assess the long term safety of the durvalumab treatment period including subsequent treatment period and demonstrate the efficacy of patients treated with durvalumab following chemoradiation therapy in the real world.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients who receive durvalumab for unresectable stage III NSCLC at first time following chemoradiation therapy.
* Patients who provided written informed consent.

Exclusion Criteria:

* Patients who would join Post Marketing Surveyllance for durvalumab.
* Patients who would join any interventional clinical studies using unapproved drugs or off-label use of drugs from first diagnosis to the end of the durvalumab treatment
* Age \< 20

Locations (43)

Nagoya, Aichi-ken, Japan
Toyoake, Aichi-ken, Japan
Matsuyama, Ehime, Japan
Kurume, Fukuoka, Japan
Maebashi, Gunma, Japan
Asahikawa, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Akashi, Hyōgo, Japan
Kobe, Hyōgo, Japan
Kasama, Ibaraki, Japan
Kanazawa, Ishikawa-ken, Japan
Morioka, Iwate, Japan
Sagamihara, Kanagawa, Japan
Yokohama, Kanagawa, Japan
Matsubara, Mie-ken, Japan
Natori-shi, Miyagi, Japan
Sendai, Miyagi, Japan
Nishihara, Okinawa, Japan
Hirakata, Osaka, Japan
Sakai, Osaka, Japan
Sayama, Osaka, Japan
Hidaka, Saitama, Japan
Izumo, Shimane, Japan
Mishima, Shizuoka, Japan
Mibu, Tochigi, Japan
Shimotsuke, Tochigi, Japan
Bunkyo, Tokyo, Japan
Chūō, Tokyo, Japan
Koto, Tokyo, Japan
Mitaka, Tokyo, Japan
+ 13 more on CT.gov